Abstracts tagged "antiphospholipid syndrome and fertility"

Abstract Number: 2554 • 2013 ACR/ARHP Annual Meeting
In Vitro Fertilization In Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A Series Of 82 Cycles
Pauline Orquevaux¹, Agathe Masseau², Véronique le Guern³, Vanessa Gayet⁴, Danièle Vauthier-Brouzes⁵, Du Boutin⁶, Bertrand Wechsler⁷, Nathalie Morel⁸, Jean Loup Pennaforte¹, Jean-Charles Piette⁹ and Nathalie Costedoat-Chalumeau¹⁰, ¹Hu Robert Debre, CHU Reims, Reims, France, ²Internal Medicine Department, Nantes University Hospital, Nantes, France, ³Department of Internal Medicine, Hôpital Cochin, Paris, France, ⁴Cochin Hospital, Paris, France, ⁵gynecology obstetrical, Pitié Salpétrière Hospital, Paris, France, ⁶Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁷Internal Medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ⁸Internal Medicine, COCHIN, Paris, France, ⁹Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France, ¹⁰Internal Medicine, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) undergoing in vitro fertilization (IVF) are at increased risk of both hormone-associated flare and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].